This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A virus from humble black-eyed peas is showing extraordinary promise in the fight against cancer. Unlike other plant viruses, the cowpea mosaic virus (CPMV) can awaken the human immune system and transform it into a cancer-fighting powerhouse, without infecting human cells.
A tiny, four-fingered 'hand' folded from a single piece of DNA can pick up the virus that causes COVID-19 for highly sensitive rapid detection and can even block viral particles from entering cells to infect them, researchers report.
Researchers used a virus to deliver a healthy copy of the OTOF gene into the inner ear, improving auditory function across all ten participants in the study. A cutting-edge gene therapy has significantly restored hearing in children and adults with congenital deafness, showing dramatic results just one month after a single injection.
Scientists in Switzerland have cracked open a century-old viral mystery by decoding the genome of the 1918 influenza virus from a preserved Zurich patient. This ancient RNA revealed that the virus had already adapted to humans at the very start of the pandemic, carrying mutations that made it both more infectious and more immune-resistant.
By analyzing thousands of samples over three years, scientists discovered that juvenile bats frequently host multiple coronaviruses simultaneously—offering a real-time window into how new strains might arise.
THURSDAY, June 12, 2025 — A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization in U.S. Food and Drug Administration (FDA) has approved a monoclonal.
A new international study reveals that ancient viral DNA buried in our genes plays an active role in controlling how other genes are turned on or off, especially during early human development. These sequences, originally from long-extinct viruses, have evolved to act like tiny genetic switches.
Murphy New treatments are sorely needed for Ebola virus infections, which cause rare, yet severe, outbreaks. Related news Imaging combined with genetic screening of cells enhances genomic discoveries Although outbreaks of Ebola virus are rare, the disease is severe and often fatal, with few treatment options.
The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to help overcome the packaging constraints of current genetic medicines.
Scientists have uncovered a stealthy tactic used by the SARS-CoV-2 virus: one of its proteins can leap from infected cells to healthy ones, effectively tricking the immune system into attacking the body’s own tissues.
Thienopyrimidines exhibit multifarious features, mainly, this is due to their structural resemblance with purine bases, such as guanine and adenine. Their intricate molecular structures enable them to interact with specific molecular targets, such as enzymes, receptors, and cellular signaling pathways, leading to their therapeutic efficacy.
The resulting compounds displayed antiviral activity against live virus that was irreversible after washout due to the covalent binding mechanism. We demonstrate the utility of this approach using the SARS-CoV-2 spike-ACE2 proteinprotein interaction and identify multiple covalent macrocyclic inhibitors that disrupt this interaction.
Combined with network pharmacology and experimental verification, this study found that platycodin D and luteolin in Jiegeng ( Platycodonis Radix ) may regulate inflammation through the IL-17 signaling pathway to treat influenza virus pneumonia.
Stunningly, blocking this single enzyme shuts the virus down completely. Researchers discovered that it actively reshapes the 3D structure of the human genome within hours of infection, using host enzymes like topoisomerase I to gain access to crucial genetic machinery.
The team has successfully created over 1000 of them, and each consist of: a harmless adeno-associated virus (or AAV) that acts like a shuttle capable of transporting specially designed DNA into the cell; a segment of DNA (an enhancer) that acts like an activation switch to mark or trigger a change in how the cell functions.
Moreover, the function of their Atp1a3 protein was restored in the brain, and their motor and cognitive deficits were ameliorated. The scientists delivered the prime editors to cells in mice using clinically validated viruses called AAVs, which are already used in FDA-approved gene therapies targeting brain cells.
Viral vectors use a virus’s blueprint to deliver genetic material into cells. Delivery methods are also key, with viral vector-based systems being the most common. The two most used vectors are Adeno-associated viruses (AAVs), which boast low immunogenicity and long-term gene expression, and lentiviruses, which offer stable gene transfer.
A significant proportion of gene therapies currently in development utilize recombinant adeno-associated virus (rAAV) vectors due to their favorable safety profile and ability to effectively deliver genetic material to target cells. However, the gene therapy sector faces its own unique set of obstacles.
But the researchers needed to deliver the base editors to the brain. Building on previous work by the vector-engineering lab of Ben Deverman at the Broad, the team developed a pair of adeno-associated viruses (AAVs) to package and deliver the base-editing machinery to brain cells.
One group set apart from the rest, and its members were particularly intriguing because they were encoded by genes with regularly spaced repetitive sequences reminiscent of an essential component of CRISPR systems. These were the TIGR-Tas systems. In some, the RNA-binding region is adjacent to a DNA-cutting part of the protein.
While elevations in liver enzyme values are recognized as a class-related side effect with adeno-associated virus (AAV)-based gene therapy, the exact mechanisms that contribute to these abnormalities remain unclear.
Initially approved for dengue fever, post-market data revealed that the vaccine increased the risk of severe disease in patients who had never been exposed to the virus before vaccination. Conversely, Sanofi’s Dengvaxia vaccine case highlights the consequences of inadequate post-market surveillance.
To shuttle the base editors to specific cells in mice, the researchers packaged them into dual AAV9 vectors, an adeno-associated virus designed to deliver cargo to neurons. The base editors stabilized the repeat tracts in mouse models of Friedreichs ataxia and Huntingtons disease.
This new monoclonal antibody therapy is designed to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in neonates and infants born during or entering their first RSV season. Food and Drug Administration (FDA) granting approval for ENFLONSIA™ (clesrovimab-cfor).
HIV antivirals may be the key to stopping HTLV-1, a deadly virus with no cure. In a decade-long study, researchers successfully suppressed the virus in mice and discovered a way to kill infected cells, offering hope for the first preventative and curative treatments.
Importantly, this will enable them to produce mRNA vaccines during periods between health crises, retaining trained personnel, technical expertise, and production capacity while retaining the ability to respond quickly in the event of future disease outbreaks.
CDC panel backs long-acting monoclonal antibody to protect infants during their first RSV season; drug also included in federal Vaccines for Children program Merck , operating as MSD outside the United States and Canada, has announced a key regulatory milestone for its respiratory syncytial virus (RSV) prevention program. As the U.S.
This update comes after two cases of fatal acute liver failure (ALF) were reported in non-ambulatory DMD patients who received Elevidys, a phenomenon that underscores the ongoing complexities and safety signals related to adeno-associated virus (AAV)-mediated gene therapy.
Sanofi Ramps Up Early Global Distribution of Beyfortus to Meet Growing RSV Season Demand, Enhancing Protection for Infants Worldwide In a proactive move to ensure readiness for the 2025-2026 respiratory syncytial virus (RSV) season, Sanofi has announced that shipments of Beyfortus® (nirsevimab) will begin in early Q3 2025.
If the same virus invades the cell a second time, the gRNA’s spacer sequence will bind to the matching viral DNA sequence, then be cut by the Cas protein. .” Despite its association with genome editing, 1 CRISPR didn’t start out as a tool for fighting genetic disease.
By binding to the active site of the protease, the drug prevents this cleavage process, effectively halting viral assembly and impeding the virus’s ability to produce future virions. [1] This protein is a crucial enzyme responsible for cleaving viral polyproteins into functional subunits essential for viral replication.
1428321-10-1 Pritelivir mesylate is an antiviral drug currently under development, specifically targeting herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). Pritelivir (development codes AIC316 or BAY 57-1293 ) is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV).
However, several of Zenrelias promotional materialsspecifically, FDA looked at a consumer-directed website, a product brochure and risk tracker, and a slide deckomitted the specific phrase from modified live virus vaccines from the boxed warning found in the Important Safety Information.
. “Because analytical questions from both manufacturers and regulators are increasing, we have to think smarter with novel technologies,” he says. “Refeyn, for example, has a technology which can investigate and provide data on the aggregation of viruses, which is a key attribute for QC release of some gene therapy drugs.”
3 Evidence on transmission of hepatitis C virus (HCV) is less clear, but in Europe, where SSPs are more widely used, high SSP use is associated with a 76% reduction in HCV transmission. Use of SSPs in places where they have been allowed to operate in the United States is associated with a 40-60% reduction in HIV transmission.
Most Popular Merck to buy Verona and its lung drug in $10B deal Trump says pharmaceutical, copper tariffs coming ‘very soon’ Deep Dive Protein degraders: chasing undruggable targets Lilly gets FDA OK of modified dosing for Alzheimer’s drug Library resources Podcast Digital Behavioral Therapy for Fibromyalgia Custom content for Medrio Webinar - on demand (..)
Most Popular Merck to buy Verona and its lung drug in $10B deal Trump says pharmaceutical, copper tariffs coming ‘very soon’ Deep Dive Protein degraders: chasing undruggable targets Lilly gets FDA OK of modified dosing for Alzheimer’s drug Library resources Podcast Digital Behavioral Therapy for Fibromyalgia Custom content for Medrio Webinar - on demand (..)
While the two treatments are constructed differently, they both use the same kind of engineered virus to deliver a replacement gene to the body’s muscles. The man died of complications from acute liver failure in June.
A cat named Pepper has once again helped scientists discover a new virus—this time a mysterious orthoreovirus found in a shrew. Researchers from the University of Florida, including virologist John Lednicky, identified this strain during unrelated testing and published its genome.
With this approval, MAVYRET becomes the first and only DAA treatment approved to treat both acute and chronic hepatitis C virus (HCV) infections in patients as young as three years old, with or without compensated cirrhosis, using an eight-week regimen. No one should die of hepatitis C.”
BT524 is a lyophilized, virus-inactivated fibrinogen concentrate that can be reconstituted and administered rapidly, ensuring a more controlled delivery of the needed clotting protein. Grifols’ BT524, developed by its subsidiary Biotest, offers a more standardized and potentially safer alternative.
One such initiative includes a collaboration with the Bill & Melinda Gates Foundation aimed at developing low-cost monoclonal antibodies (mAbs) for infectious diseases such as malaria and respiratory syncytial virus (RSV). This partnership has recently reached a key milestone, resulting in a second disbursement of $1.5 million award.
Scientists have uncovered over 200 new giant viruses lurking in ocean waters that not only help shape marine ecosystems but also manipulate photosynthesis in algae. These massive viruses once nearly invisible to science are now being exposed using powerful supercomputing and a new tool called BEREN.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content